The Therapeutic Goods Administration (TGA) has approved Pfizer Australia and BioNTech SE’s XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for individuals aged 5 and over. The decision follows evidence that this vaccine can better protect against symptomatic and severe COVID-19. The vaccine is free and available at pharmacies and general practices across Australia.
Tariff support for health IT launched in South Korea following Trump’s tariff and more briefs
The South Korean government has launched a tariff support center to assist medical device companies with trade challenges, particularly related to U.S. tariffs. Meanwhile, Johnson
